Innovation award recognises STIMULAN Rapid Cure as the only calcium sulfate antibiotic carrier approved for use in bone and soft tissue
International Trade award recognises Biocomposites’ outstanding continuous growth in overseas sales
KEELE, England, April 21, 2022 /PRNewswire/ — Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is delighted to have been honoured with two Queen’s Awards for Enterprise for Innovation and International Trade.
Biocomposites is one of only seven organisations nationally to achieve two Queen’s Awards in 2022.
The Queen’s Awards for Enterprise is one of the world’s most distinguished business awards, celebrating and recognising enterprise excellence in UK companies. Announced annually by Her Majesty the Queen, the awards follow a rigorous and highly competitive judging process and are only bestowed on organisations that maintain the highest levels of business excellence.
Established in Staffordshire in 1997, Biocomposites now employs over 200 people and specialises in the development of innovative calcium compounds for surgical use, targeting infection risks across musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, and podiatry.
Biocomposites has been recognised in the Innovation category for the innovative development of STIMULAN® Rapid Cure, the first and only calcium sulfate antibiotic…
